Germline Panel – Prostate Cancer

Test Code
SLS161008
Book Now

What is the Germline Panel - Prostate Cancer?

Prostate cancer has a significant hereditary component, with approximately 10-15% of metastatic prostate cancers linked to inherited mutations. BRCA2 mutations, in particular, are associated with aggressive prostate cancer and influence treatment decisions, including eligibility for PARP inhibitors.

The Germline Panel – Prostate Cancer examines genes associated with hereditary prostate cancer, including BRCA1, BRCA2, and other DNA repair genes.

Additionally, mismatch repair (MMR) genes are also included, as Lynch syndrome is linked to an increased risk of prostate and other cancers.

Genes Covered/No of Genes: ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, TP53

Indications for Testing

  • Men diagnosed with prostate cancer at <55 years.
  • Individuals with a family history of hereditary prostate or Breast cancer/ovarian carcinoma.
  • Patients eligible for PARP inhibitor therapy.

Inheritance Pattern

Autosomal dominant—BRCA2 mutations in particular significantly increase aggressive prostate cancer risk.

Why is This Test Important?

Testing can guide active surveillance, surgical decisions, and targeted therapies.
Prostate Cancer

Contact Us